Last reviewed · How we verify
Antivert (meclizine)
Antivert (generic name: meclizine) is a Antihistamine/Antiemetic (vestibular suppressant) Small molecule drug developed by Generic (originally Pfizer/UCB). It is currently FDA-approved (first approved 1957) for Motion sickness, Prevention of Motion Sickness, Vertigo. Also known as: Antivert, Bonine, Dramamine Less Drowsy.
Meclizine, also known as Antivert, is a small molecule antihistamine used to treat motion sickness and dizziness (vertigo). It is taken by mouth and its effects typically begin within an hour, lasting for up to a day.
At a glance
| Generic name | meclizine |
|---|---|
| Also known as | Antivert, Bonine, Dramamine Less Drowsy |
| Sponsor | Generic (originally Pfizer/UCB) |
| Drug class | Antihistamine/Antiemetic (vestibular suppressant) |
| Target | Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1957-01-01 (United States) |
Approved indications
- Motion sickness
- Prevention of Motion Sickness
- Vertigo
Common side effects
Key clinical trials
- A Randomized Trial to Evaluate Resolution of Symptoms Using Vestibular Rehab Versus Conventional Therapy in Patients Presenting to the Emergency Department (ED) With Diagnosis of Benign Paroxysmal Pos (NA)
- A Pilot Study of the Effects of Meclizine on Pre-Pulse Inhibition (Phase 1)
- A Window of Opportunity Trial with Meclizine in Hepatocellular Carcinoma (Phase 1)
- Optimizing the Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance. Motion Sickness Countermeasures Fie (Phase 2)
- Real-time Decision Support for Postoperative Nausea and Vomiting (PONV) Prophylaxis (NA)
- Meclizine as a Potential Smoking Cessation Treatment (Phase 2)
- A New Dual Function Oro-Dissolvable/Dispersible Meclizine HCL Tablet to Challenge Patient Inconvenience: In-Vitro Evaluation and In-Vivo Assessment in Human Volunteers (Phase 1)
- Motion Sickness Medications and Vestibular Time Constant (Phase 4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Antivert CI brief — competitive landscape report
- Antivert updates RSS · CI watch RSS
- Generic (originally Pfizer/UCB) portfolio CI
Frequently asked questions about Antivert
What is Antivert?
What is Antivert used for?
Who makes Antivert?
What is the generic name of Antivert?
Is Antivert also known as anything else?
What drug class is Antivert in?
When was Antivert approved?
What development phase is Antivert in?
What does Antivert target?
Related
- Drug class: All Antihistamine/Antiemetic (vestibular suppressant) drugs
- Target: All drugs targeting Nuclear receptor subfamily 1 group I member 3, Serine protease hepsin, Histamine H1 receptor
- Manufacturer: Generic (originally Pfizer/UCB) — full pipeline
- Therapeutic area: All drugs in Other
- Indication: Drugs for Motion sickness
- Indication: Drugs for Prevention of Motion Sickness
- Indication: Drugs for Vertigo
- Also known as: Antivert, Bonine, Dramamine Less Drowsy
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing